Axogen's Ownership Structure: Institutional Dominance and Insider Sales
ByAinvest
Sunday, Aug 31, 2025 9:31 am ET1min read
AXGN--
A total of 12 investors, including Quantbot Technologies LP, Wyoming State, Fifth Third Bancorp, GAMMA Investing LLC, Zurcher Kantonalbank Zurich Cantonalbank, and KLP Kapitalforvaltning AS, hold a majority stake in the company, accounting for 52% of the shares. However, hedge funds do not have a significant presence in AxoGen, with only 81 institutional investors adding shares to their portfolios and 102 decreasing their positions in the most recent quarter [2].
Quantbot Technologies LP, for instance, recently purchased 34,182 shares valued at approximately $632,000, bringing its ownership to 0.08% of AxoGen. This acquisition follows a series of strategic moves by other institutional investors who have either increased their stakes or initiated new positions in the company [1].
The recent SEC filings also indicate that several other institutional investors have made notable changes to their positions in AxoGen. Wyoming State bought a new position valued at $31,000 during the fourth quarter, while Fifth Third Bancorp acquired a new stake valued at $92,000 during the first quarter. GAMMA Investing LLC raised its holdings by 3,884.6% during the first quarter, owning 5,698 shares valued at $105,000 after buying an additional 5,555 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank and KLP Kapitalforvaltning AS also initiated new stakes valued at $146,000 and $150,000, respectively [1].
The high level of institutional ownership in AxoGen suggests that the stock price may be influenced by the collective actions of these large shareholders. However, the absence of a significant hedge fund presence may provide some stability to the stock price, as hedge funds are often seen as more aggressive traders.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-quantbot-technologies-lp-purchases-new-shares-in-axogen-inc-axgn-2025-08-26/
[2] https://www.quiverquant.com/news/Axogen%2C+Inc.+Receives+FDA+Extension+for+Avance%C2%AE+Nerve+Graft+Biologics+License+Application+Review
Axogen, Inc. is heavily dominated by institutional owners with 88% ownership. This suggests that the stock price may be vulnerable to their trading decisions. A total of 12 investors have a majority stake in the company with 52% ownership. However, hedge funds do not have a significant presence in Axogen.
AxoGen, Inc. (NASDAQ: AXGN) has seen a significant shift in institutional ownership, with 88% of the company's stock now held by institutional investors. This high level of institutional ownership suggests that the stock price may be sensitive to the trading decisions of these large shareholders [1].A total of 12 investors, including Quantbot Technologies LP, Wyoming State, Fifth Third Bancorp, GAMMA Investing LLC, Zurcher Kantonalbank Zurich Cantonalbank, and KLP Kapitalforvaltning AS, hold a majority stake in the company, accounting for 52% of the shares. However, hedge funds do not have a significant presence in AxoGen, with only 81 institutional investors adding shares to their portfolios and 102 decreasing their positions in the most recent quarter [2].
Quantbot Technologies LP, for instance, recently purchased 34,182 shares valued at approximately $632,000, bringing its ownership to 0.08% of AxoGen. This acquisition follows a series of strategic moves by other institutional investors who have either increased their stakes or initiated new positions in the company [1].
The recent SEC filings also indicate that several other institutional investors have made notable changes to their positions in AxoGen. Wyoming State bought a new position valued at $31,000 during the fourth quarter, while Fifth Third Bancorp acquired a new stake valued at $92,000 during the first quarter. GAMMA Investing LLC raised its holdings by 3,884.6% during the first quarter, owning 5,698 shares valued at $105,000 after buying an additional 5,555 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank and KLP Kapitalforvaltning AS also initiated new stakes valued at $146,000 and $150,000, respectively [1].
The high level of institutional ownership in AxoGen suggests that the stock price may be influenced by the collective actions of these large shareholders. However, the absence of a significant hedge fund presence may provide some stability to the stock price, as hedge funds are often seen as more aggressive traders.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-quantbot-technologies-lp-purchases-new-shares-in-axogen-inc-axgn-2025-08-26/
[2] https://www.quiverquant.com/news/Axogen%2C+Inc.+Receives+FDA+Extension+for+Avance%C2%AE+Nerve+Graft+Biologics+License+Application+Review
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet